Oral versus intravenous steroids for treatment of relapses in multiple sclerosis

Abstract

The analysis of the five included trials comparing intravenous versus oral steroid therapy for MS relapses do not demonstrate any significant differences in clinical (benefits and adverse events), radiological or pharmacological outcomes. Based on the evidence, oral steroid therapy may be a practical and effective alternative to intravenous steroid therapy in the treatment of MS relapses.

High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient’s satisfaction

“…The statistical analysis showed that oral MP was non-inferior to intravenous MP. This is similar to data published in previous studies 4 8 9 13–17…”

High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient’s satisfaction

“…The statistical analysis showed that oral MP was non-inferior to intravenous MP. This is similar to data published in previous studies 4 8 9 13–17…”

Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials

“…Therefore, in order to avoid insomnia, we recommend taking oMP in the morning. A systematic review written by Burton [ 17 ] comparing oral versus intravenous methylprednisolone also revealed that there was no statistically significant difference between the two routes of steroid administration in the proportion of patients who improved at 4 weeks, a finding that is consistent with our efficacy outcome. In addition, this study reported that oMP and ivMP were equally safe and well tolerated except a tendency towards more cases of dysgeusia and mood disturbance with oral steroid administration.…”

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

“…However, the tolerability was similar for both regimens, except for insomnia, which was more frequent in the oral group than in the intravenous group, even though patients could receive the corticosteroids at any time of day. This was also reported in the meta-analysis, 12 and might be due to prolonged bioavailability. We therefore recommend giving the oral treatment in the morning.…”

High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient’s satisfaction

“…The statistical analysis showed that oral MP was non-inferior to intravenous MP. This is similar to data published in previous studies 4 8 9 13–17…”

Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials

“…Therefore, in order to avoid insomnia, we recommend taking oMP in the morning. A systematic review written by Burton [ 17 ] comparing oral versus intravenous methylprednisolone also revealed that there was no statistically significant difference between the two routes of steroid administration in the proportion of patients who improved at 4 weeks, a finding that is consistent with our efficacy outcome. In addition, this study reported that oMP and ivMP were equally safe and well tolerated except a tendency towards more cases of dysgeusia and mood disturbance with oral steroid administration.…”

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

“…However, the tolerability was similar for both regimens, except for insomnia, which was more frequent in the oral group than in the intravenous group, even though patients could receive the corticosteroids at any time of day. This was also reported in the meta-analysis, 12 and might be due to prolonged bioavailability. We therefore recommend giving the oral treatment in the morning.…”

High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient’s satisfaction

“…The statistical analysis showed that oral MP was non-inferior to intravenous MP. This is similar to data published in previous studies 4 8 9 13–17…”

Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials

“…Therefore, in order to avoid insomnia, we recommend taking oMP in the morning. A systematic review written by Burton [ 17 ] comparing oral versus intravenous methylprednisolone also revealed that there was no statistically significant difference between the two routes of steroid administration in the proportion of patients who improved at 4 weeks, a finding that is consistent with our efficacy outcome. In addition, this study reported that oMP and ivMP were equally safe and well tolerated except a tendency towards more cases of dysgeusia and mood disturbance with oral steroid administration.…”

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

“…However, the tolerability was similar for both regimens, except for insomnia, which was more frequent in the oral group than in the intravenous group, even though patients could receive the corticosteroids at any time of day. This was also reported in the meta-analysis, 12 and might be due to prolonged bioavailability. We therefore recommend giving the oral treatment in the morning.…”